Wed, February 15, 2012
Tue, February 14, 2012
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ]: Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
[ Mon, Feb 06th 2012 ]: Market Wire
Pfizer, Gap, Wells Fargo
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ]: Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012

Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Leerink Swann 2012 Global Healthcare Conference on February 15, 201


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. al-healthcare-conference-on-february-15-201.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Leerink Swann 2012... -- SAN DIEGO, Feb. 9, 2012 /PRNewswire/ --

Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Leerink Swann 2012 Global Healthcare Conference on February 15, 2012

[ ]

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: [ CADX ]), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, February 15, 2012 at 8:00am Eastern Time (5:00am Pacific Time) during the Leerink Swann 2012 Global Healthcare Conference at the Waldorf Astoria Hotel in New York City.           

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at [ www.cadencepharm.com ] on the Investor Relations page.  A replay of the webcast will available approximately three hours after the live webcast concludes and will remain available for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. In January 2011, Cadence commercially launched OFIRMEV™ (acetaminophen) injection, an intravenous formulation of acetaminophen, in the U.S.  For more information about Cadence, please visit [ www.cadencepharm.com ].

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Contacts:

William R. LaRue

 

SVP, CFO

 

Cadence Pharmaceuticals, Inc.

 

858-436-1400

SOURCE Cadence Pharmaceuticals

[ Back to top ]

RELATED LINKS
[ http://www.cadencepharm.com ]


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear